• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Genetic testing and molecular biomarkers >Association Analysis of the Brain-Derived Neurotrophic Factor Gene Val66Met Polymorphism and Gender with Efficacy of Antidepressants in the Chinese Han Population with Generalized Anxiety Disorder
【24h】

Association Analysis of the Brain-Derived Neurotrophic Factor Gene Val66Met Polymorphism and Gender with Efficacy of Antidepressants in the Chinese Han Population with Generalized Anxiety Disorder

机译：协会的分析脑源性神经营养因子基因Val66Met多态性和性别与抗抑郁药的疗效中国汉族人口与广义焦虑性障碍

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background and Aim: This study was designed to explore the relationship between the brain-derived neurotrophic factor (BDNF) Val66Met polymorphism and antidepressants' efficacy in the Chinese Han population with generalized anxiety disorder (GAD). Materials and Methods: We recruited 206 patients who met the diagnostic criteria for GAD into the test group, and assigned 209 healthy participants to the control group. All participants were genotyped for the BDNF Val66Met polymorphism. GAD patients were treated with escitalopram or extended-release venlafaxine. We used the Hamilton Rating Scale for Anxiety (HAM-A) to assess the response to 8-weeks of antidepressant treatment for GAD. Results: We did not identify any significant differences in the allelic or genotype frequencies of the BDNF Val66Met polymorphism between the test and control group. Furthermore, we did not detect any significant difference in the allele or genotype frequency of BDNF Val66Met between patients with different treatment responses. Finally, we did not detect any significant difference in the HAM-A score reduction rate among patients with different genotypes, gender, or treatment drugs. Conclusions: No significant difference was found in the BDNF Val66Met polymorphism between patients with GAD and healthy controls. The BDNF Val66Met polymorphism was not significantly associated with antidepressant drug efficacy for GAD.
机译：背景和目的:本研究旨在探索之间的关系脑源性神经营养因子(BDNF) Val66Met多态性和抗抑郁药物的疗效中国汉族人口与广泛性焦虑症迦得障碍()。招募了206名病人诊断迦得的标准测试组,和分配209健康的参与者控制组。BDNF Val66Met多态性。处理酞或延长释放文拉法辛。焦虑(HAM-A)评估的响应8周的抗抑郁治疗广泛性焦虑症。结果:我们没有确定任何重大等位基因和基因型的差异频率的BDNF Val66Met多态性在测试和对照组之间。我们没有发现任何显著性差异BDNF Val66Met的等位基因和基因型频率患者不同治疗响应。HAM-A得分显著差异患者降低率不同基因型、性别或治疗药物。结论:没有发现显著差异之间的BDNF Val66Met多态性广泛性焦虑症患者和健康对照组。Val66Met多态性并不显著与抗抑郁药物疗效

著录项

相似文献

  • 外文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号